{"title":"治疗严重哮喘的生物疗法。","authors":"Silvano Dragonieri, Giovanna Elisiana Carpagnano","doi":"10.1186/s40733-021-00078-w","DOIUrl":null,"url":null,"abstract":"<p><p>Around 5-10% of the total asthmatic population suffer from severe or uncontrolled asthma, which is associated with increased mortality and hospitalization, increased health care burden and worse quality of life. In the last few years, new drugs have been launched and several asthma phenotypes according to definite biomarkers have been identified. In particular, therapy with biologics has revolutionized the management and the treatment of severe asthma, showing high therapeutic efficacy associated with significant clinical benefits. To date, four types of biologics are licensed for severe asthma, i.e. omalizumab (anti-immunoglobulin E) antibody, mepolizumab and reslizumab (anti-interleukin [IL]-5antibody), benralizumab (anti-IL-5 receptor a antibody) and dupilumab (anti-IL-4 receptor alpha antibody). The aim of this article was to review the biologic therapies currently available for the treatment of severe asthma, in order to help physicians to choose the most suitable biologic agent for their asthmatic patients.</p>","PeriodicalId":8572,"journal":{"name":"Asthma research and practice","volume":"7 1","pages":"12"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362167/pdf/","citationCount":"0","resultStr":"{\"title\":\"Biological therapy for severe asthma.\",\"authors\":\"Silvano Dragonieri, Giovanna Elisiana Carpagnano\",\"doi\":\"10.1186/s40733-021-00078-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Around 5-10% of the total asthmatic population suffer from severe or uncontrolled asthma, which is associated with increased mortality and hospitalization, increased health care burden and worse quality of life. In the last few years, new drugs have been launched and several asthma phenotypes according to definite biomarkers have been identified. In particular, therapy with biologics has revolutionized the management and the treatment of severe asthma, showing high therapeutic efficacy associated with significant clinical benefits. To date, four types of biologics are licensed for severe asthma, i.e. omalizumab (anti-immunoglobulin E) antibody, mepolizumab and reslizumab (anti-interleukin [IL]-5antibody), benralizumab (anti-IL-5 receptor a antibody) and dupilumab (anti-IL-4 receptor alpha antibody). The aim of this article was to review the biologic therapies currently available for the treatment of severe asthma, in order to help physicians to choose the most suitable biologic agent for their asthmatic patients.</p>\",\"PeriodicalId\":8572,\"journal\":{\"name\":\"Asthma research and practice\",\"volume\":\"7 1\",\"pages\":\"12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362167/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asthma research and practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s40733-021-00078-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asthma research and practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40733-021-00078-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
哮喘患者总数中约有 5-10%患有严重或无法控制的哮喘,这与死亡率和住院率增加、医疗负担加重和生活质量下降有关。在过去几年中,新药相继问世,并根据明确的生物标志物确定了几种哮喘表型。尤其是生物制剂的治疗彻底改变了重症哮喘的管理和治疗,显示出与显著临床疗效相关的高疗效。迄今为止,已有四种生物制剂获得了治疗重症哮喘的许可,即奥马珠单抗(抗免疫球蛋白 E 抗体)、美博利珠单抗和雷利珠单抗(抗白细胞介素 [IL]-5 抗体)、苯拉珠单抗(抗 IL-5 受体 a 抗体)和杜匹单抗(抗 IL-4 受体 alpha 抗体)。本文旨在回顾目前可用于治疗重症哮喘的生物疗法,以帮助医生为哮喘患者选择最合适的生物制剂。
Around 5-10% of the total asthmatic population suffer from severe or uncontrolled asthma, which is associated with increased mortality and hospitalization, increased health care burden and worse quality of life. In the last few years, new drugs have been launched and several asthma phenotypes according to definite biomarkers have been identified. In particular, therapy with biologics has revolutionized the management and the treatment of severe asthma, showing high therapeutic efficacy associated with significant clinical benefits. To date, four types of biologics are licensed for severe asthma, i.e. omalizumab (anti-immunoglobulin E) antibody, mepolizumab and reslizumab (anti-interleukin [IL]-5antibody), benralizumab (anti-IL-5 receptor a antibody) and dupilumab (anti-IL-4 receptor alpha antibody). The aim of this article was to review the biologic therapies currently available for the treatment of severe asthma, in order to help physicians to choose the most suitable biologic agent for their asthmatic patients.
期刊介绍:
Asthma Research and Practice is the official publication of Interasma and publishes cutting edge basic, clinical and translational research in addition to hot topic reviews and debate articles relevant to asthma and related disorders (such as rhinitis, COPD overlapping syndrome, sinusitis). The journal has a specialized section which focusses on pediatric asthma research. Asthma Research and Practice aims to serve as an international platform for the dissemination of research of interest to pulmonologists, allergologists, primary care physicians and family doctors, ENTs and other health care providers interested in asthma, its mechanisms and comorbidities.